Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ahmer Ali

Sleep Medicine Lake Barrington, IL Medical Doctor

NPI 1275825978 CMS profile 2476157

22285 N Pepper Rd, Suite 401, Lake Barrington, IL 60010

Open in the dashboard

General payments

$14,956

896 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ahmer Ali of Lake Barrington, IL is reported in the CMS Open Payments database as having received $14,956 across 896 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,691 190
2024 General $2,876 165
2023 General $2,152 131
2022 General $2,029 143
2021 General $2,658 177
2020 General $885 63
2019 General $666 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ahmer Ali
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to Ahmer Ali were reported at $3,691. Among 263 Sleep Medicine profiles paid that year, the median was $337 and the middle half received between $114 and $1,241.

Show as a table
Year Ahmer Ali Sleep Medicine median Middle half National median
2019 $666 $206 $79–$855 $163
2020 $885 $170 $48–$1,437 $114
2021 $2,658 $178 $53–$1,297 $132
2022 $2,029 $313 $95–$1,332 $149
2023 $2,152 $307 $117–$1,081 $160
2024 $2,876 $308 $100–$1,432 $164
2025 $3,691 $337 $114–$1,241 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,813 292 payments
  2. Pfizer Inc. $1,482 132 payments
  3. Harmony Biosciences LLC $1,280 51 payments
  4. Teva Pharmaceuticals USA, Inc. $815 58 payments
  5. UCB, Inc. $765 24 payments
  6. Lilly USA, LLC $714 31 payments
  7. Biohaven Pharmaceuticals, Inc. $596 53 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $545 57 payments
  9. Novartis Pharmaceuticals Corporation $436 18 payments
  10. TG Therapeutics, Inc. $432 4 payments
  11. Other $4,079 176 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,512 892 payments
  2. Education $295 3 payments
  3. Consulting Fee $150 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY $2,521 215 payments
  2. QULIPTA $2,068 153 payments
  3. NURTEC ODT Pain $1,439 130 payments
  4. ZAVZPRET $1,142 102 payments
  5. NURTEC ODT Primary Care $1,140 110 payments
  6. AJOVY $611 50 payments
  7. AIMOVIG $574 29 payments
  8. Wakix $530 20 payments
  9. BOTOX $529 22 payments
  10. Briviact $472 15 payments
  11. Other $7,170 299 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

1,571

Median for Neurology: 833

Drug cost

$236,686

Median for Neurology: $202,670

Branded share of claims

20.6%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Briviact Brivaracetam Brand 52 $72,018
Ubrelvy Ubrogepant Brand 15 $30,752
Xcopri Cenobamate Brand 26 $29,389
Sunosi Solriamfetol Hcl Brand 21 $18,047
Neupro Rotigotine Brand 19 $15,954
Belsomra Suvorexant Brand 34 $14,602
Carbamazepine Er Carbamazepine Brand 21 $8,101
Dilantin Phenytoin Sodium Extended Brand 12 $7,353
Lacosamide Generic 90 $6,168
Levetiracetam Generic 113 $4,258

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$171,814

Of which drugs: $43,599

Medicare patients

534

Average age 74

Services billed

4,617

266 women, 268 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 34%
Ischemic heart disease 33%
Depression 30%
Atrial fibrillation 26%
Chronic kidney disease 26%
Heart failure 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadobutrol, 0.1 ml A9585 Office 18 1,600 $392

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
$473 — —
UBRELVY
$392 15 —
NURTEC ODT
$300 — —
ZAVZPRET
$190 — —
BOTOX
$184 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

896 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sleep Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record